An early cautionary tale in the development of CAR T-cell therapy for solid cancers came in 2010 when a patient with chemotherapy-refractory advanced colon cancer was treated with a third0generation CAR T-cell product targeting Her2. The gene discussed is ERBB2; the disease is colonic neoplasm.